FUSCC Refractory TNBC Platform Study (FUTURE2.0)

NCT05749588 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: A1: SHR-A1811
DRUG: A2: SHR-A1811 with Camrelizumab with famitinib
DRUG: B1: TROP2 ADC
DRUG: B2: TROP2 ADC with Camrelizumab
DRUG: C1: SHR-A1811
DRUG: C2: SHR-A1811 with BP102
DRUG: D1: TROP2 ADC
DRUG: D2: TROP2 ADC with BP102
DRUG: E1: SHR-A1811
DRUG: F1: TROP2 ADC
DRUG: G1: SHR-A1811
DRUG: H1: TROP2 ADC
DRUG: E2: SHR-A1811 with everolimus
DRUG: TQB2102 with TQB2868

Sponsor

Fudan University